The prostate cancer antigen 3 (PCA3) test looks for genetic material (messenger RNA (mRNA)) produced exclusively by the prostate. In normal prostate tissue, the protein PCA3 and its associated mRNA are present at low levels. PCA3 is found in high concentrations (overexpressed) in approximately 90% of prostate cancers.
Prostate specific antigen (PSA) is also increased in prostate cancers, but it can also be increased in a variety of benign conditions. This test detects PCA3 mRNA and PSA mRNA in the first urine sample obtained after a digital rectal exam (DRE). The PCA3 score is reported by laboratories and is based on the ratio of PCA3 mRNA to PSA mRNA.
Data Bridge Market Research analyses that the prostate cancer antigen 3 (PCA3) test market which was USD 3.2 billion in 2021, is expected to reach USD 7.64 billion by 2029, at a CAGR of 11.50% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
The prostate cancer antigen 3 gene (PCA3) test is used to assess your risk of developing prostate cancer. It is not used to make a diagnosis of prostate cancer. It is primarily used to determine whether your elevated prostate-specific antigen (PSA) levels are the result of prostate cancer. Prostate cancer is a type of cancer that develops in the prostate gland of men and is increasing at a significant rate each year. This cancer is commonly found in the elderly population, and it can have serious consequences such as blood in the sperm, bone pain, and erectile dysfunction, among others. As a result, early detection is required to avoid it at an early stage.
Get PDF Sample of the Report:- https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-antigen-3-pca3-test-market
Global Prostate Cancer Antigen 3 (PCA3) Test Market Scope and Market Size
Prostate cancer antigen 3 (PCA3) test market is segmented on the basis of type of test, test type, technology, end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
· On the basis of type of test, the market is segmented into instruments, kits and reagent and consumables
· On the basis of test type, the market is segmented into molecular, and serology
· On the basis of technology, RT-PCR, ELISA test, micro-neutralization assays
· On the basis of end use, the market is segmented into hospitals, clinics, public health labs, private or commercial labs, physician labs, research institutes, and others
Prostate Cancer Antigen 3 (PCA3) Test Market Country Level Analysis
Prostate cancer antigen 3 (PCA3) Test market is analysed and market size insights and trends are provided by country, type of test, test type, technology, end use as referenced above.
The countries covered in the prostate cancer antigen 3 (PCA3) Test market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has accounted highest share in the market whereas anticipated to dominate the market due to the increasing prevalence of prostate cancer, rising geriatric population, increasing government initiative to spread awareness about early diagnosis are the factors driving the market growth in the region. Moreover, the rising demand for efficient diagnosis and advancement in technology is also expanding market growth.
Asia-Pacific is anticipated to witness the fastest growth rate in the forecast period due to increasing health insurance schemes, government initiatives to develop healthcare infrastructure, and rising geriatric population. Moreover, the changing lifestyle is also a factor behind increasing the rate number of patients.
The country section of the prostate cancer antigen 3 (PCA3) test market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Get TOC Details of the Report:- https://www.databridgemarketresearch.com/toc/?dbmr=global-prostate-cancer-antigen-3-pca3-test-market
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Prostate cancer antigen 3 (PCA3) test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Prostate Cancer Antigen 3 (PCA3) Test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the prostate cancer antigen 3 (PCA3) test market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Prostate Cancer Antigen 3 (PCA3) Test Market Share Analysis
Prostate cancer antigen 3 (PCA3) test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to prostate cancer antigen 3 (PCA3) test market.
The major players operating in the prostate cancer antigen 3 (PCA3) test market report are MDxHealth, Myriad Genetics, Inc., Abbott, F. Hoffmann-La Roche Ltd, Siemens, OPKO Health, Inc., Genomic Health, BD, Agilent Technologies, Inc., and Danaher among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Browse in-depth Research Report:- https://www.databridgemarketresearch.com/reports/global-prostate-cancer-antigen-3-pca3-test-market
Customization Available: Prostate Cancer Antigen 3 (PCA3) Test Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
TOP TRENDING HEALTHCARE REPORT
https://www.databridgemarketresearch.com/reports/global-hereditary-testing-market
https://www.databridgemarketresearch.com/reports/global-cutaneous-lupus-erythematosus-market
https://www.databridgemarketresearch.com/reports/global-portable-radiography-equipment-market
https://www.databridgemarketresearch.com/reports/global-glycohemoglobin-analyzer-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian